肿瘤细胞治疗研究
英文原题：A comprehensive bibliometric analysis (2000-2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer.
A comprehensive bibliometric analysis (2000-2022) on the mapping of knowledge regarding immunotherapeutic treatments for advanced, recurrent, or metastatic cervical cancer.
这项开创性研究详细呈现了 A/R/M 宫颈癌免疫治疗研究的全景。
背景：尽管有关宫颈癌治疗策略的文献丰富，但尚无专门聚焦晚期、复发或转移性（A/R/M）宫颈恶性肿瘤免疫治疗的文献计量学分析。本研究旨在弥补这一空白，全面呈现该研究领域的总体特征、研究重点、演变轨迹和当前新兴趋势。方法：系统检索 Web of Science 核心合集（WOSCC），识别 2000 至 2022 年发表的 A/R/M 宫颈癌相关论文。主要采用 CiteSpace 和 VOSviewer，识别研究重点与值得关注的未来趋势，并评估作者、机构、国家及期刊的贡献和共现关系。结果：共纳入 1,001 篇原创论文，涉及 66 个国家的 6,387 名作者和 1,474 家机构，发表于 366 种学术期刊。美国贡献最大。莱顿大学医学中心的 Van der Burg SH 是发表成果最多的研究者。《International Journal of Cancer》和《Cancer Research》分别是发文量最多和影响力最大的期刊。共被引聚类分析识别出 25 个聚类，主要聚焦潜在预测性生物标志物、树突状细胞肿瘤疫苗、治疗性 HPV 疫苗、肽类癌症疫苗、肿瘤免疫微环境及过继细胞转移（ACT）。关键词和参考文献突现分析显示，A/R/M 宫颈癌免疫治疗的最新重要趋势包括 ACT、CAR-T 和免疫检查点抑制剂（ICI）。结论：本开创性研究详尽呈现了 A/R/M 宫颈癌免疫治疗研究全貌，强调全球合作的重要性，加深了对该疾病免疫学的理解，拓展了对可能获益人群的认识，并探讨了多种疗法（包括治疗性疫苗、过继细胞转移和 ICI）的临床应用，尤其是它们与化疗、放疗和靶向治疗等既有疗法的联合应用。
BACKGROUND: Despite extensive literature on therapeutic strategies for cervical cancer, a bibliometric analysis specifically focused on immunotherapy for advanced, recurrent, or metastatic (A/R/M) cervical malignancies remains unexplored. This study aims to address this gap by presenting a comprehensive overview that includes general characteristics, research focal points, the trajectory of evolution, and current emerging trends in this under-researched area. METHODS: A systematic search was conducted using the Web of Science Core Collection (WOSCC) to identify articles related to A/R/M cervical cancer published between 2000 and 2022. Citespace and VOS viewer were the primary tools used to identify research focal points, intriguing future patterns, and to evaluate contributions and co-occurrences among authors, institutions, countries, and journals. RESULTS: A total of 1,001 original articles were identified, involving 6,387 authors from 66 countries and 1,474 institutions, and published across 366 academic journals. The United States contributed most significantly. The most productive researcher was Van der Burg SH from Leiden University Medical Center. The International Journal of Cancer and Cancer Research were identified as the most productive and influential journals, respectively. Analysis of co-citation clusters highlighted 25 clusters, primarily focusing on potential predictive biomarkers, dendritic cell-based tumor vaccines, therapeutic HPV vaccinations, peptide-based cancer vaccines, tumor immune microenvironments, and adoptive cell transfer (ACT). The latest significant trends in A/R/M cervical cancer immunotherapy research included ACT, CAR-T, and immune checkpoint inhibitors (ICIs), as revealed by keyword and reference burst detection. CONCLUSION: This pioneering study provides a detailed landscape of immunotherapy research in A/R/M cervical cancer. It underscores the importance of global collaboration, enriches our understanding of the immunology of A/R/M cervical cancer, expands on potential beneficiaries of immunotherapy, and explores clinical applications of various therapies, including therapeutic vaccines, adoptive cell transfer, and ICIs, particularly in combination with established treatments such as chemotherapy, radiotherapy, and targeted therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
